RxDoctor Payments Data

Jacob Witt, MD

Radiation Oncology · O Fallon, ILNPI 1891157871

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 466 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,518, 5.2 times the $485 reported in 2019. Among radiation oncology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,083in general payments, 2019–2025

Across 466 payments — averaging $21.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Merck$802
  • Johnson & Johnson$650
  • AstraZeneca$606
  • Raysearch Laboratories AB (publ)$485
  • Incyte Corporation$479
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$10,083100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis62$1,201
Merck40$802
Johnson & Johnson32$650
AstraZeneca(2 entities)29$606
Raysearch Laboratories AB (publ)1$485
Incyte Corporation29$479
Takeda Pharmaceuticals U.S.A., Inc.19$467
AbbVie17$388
Pfizer20$343
Bayer17$336
Amgen13$316
Jazz Pharmaceuticals Inc.10$279
Regeneron Healthcare Solutions, Inc.11$266
Daiichi Sankyo Inc.10$241
Stemline Therapeutics Inc.10$222
Lilly USA, LLC11$192
EMD Serono, Inc.7$191
Sobi, Inc8$169
Genentech USA, Inc.7$151
Seagen Inc.7$150
Exelixis Inc.6$148
Genmab U.S., Inc.6$142
Sanofi6$140
Coherus Oncology, Inc.7$139
Rigel Pharmaceuticals, Inc.7$108
Penumbra, Inc.1$107
Adaptive Biotechnologies Corporation4$73
Eisai Inc.4$72
AVEO Pharmaceuticals, Inc.4$71
Novocure Inc.4$69
Astellas Pharma US Inc3$68
Taiho Oncology, Inc.4$64
Boehringer Ingelheim3$63
Servier Pharmaceuticals LLC3$63
Blueprint Medicines Corporation3$59
G1 Therapeutics, Inc.3$57
Morphosys, US Inc.3$53
Immunocore Limited2$51
Mirati Therapeutics, Inc.3$47
Amneal Pharmaceuticals LLC2$46
Tersera Therapeutics LLC2$37
GSK2$36
Tolmar, Inc.2$32
Tactile Systems Technology Inc2$31
ADC Therapeutics America, Inc.2$28
Beigene USA, Inc.1$26
Pharmacyclics LLC, An Abbvie Company1$24
Tempus AI, Inc1$23
Clovis Oncology, Inc.1$23
Pharmaessentia USA Corporation1$22
Geron Corporation1$22
Beone Medicines USA, Inc.1$21
Siemens Medical Solutions USA, Inc.1$20
Syndax Pharmaceuticals, Inc.1$19
Spectrum Pharmaceuticals Inc.1$19
Agios Pharmaceuticals, Inc.1$19
Pharmacosmos Therapeutics Inc.1$18
Karyopharm Therapeutics Inc.1$17
Accord Healthcare, Inc.1$16
Gilead1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,083 in reported general payments places this provider in the 90th percentile of 242 radiation oncology providers in Illinois.

See all radiation oncology providers in Illinois

Medicare billing

Part B allowed, 2024
$683,054
Medicare patients
256
Services billed
11,139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tamsulosin Hcl60$548
Mometasone Furoate22$476
Lidocaine Hcl ViscousLidocaine Hcl46$435
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen30$421
Dexamethasone34$282
Morphine Sulfate ErMorphine Sulfate12$190
Ondansetron Hcl15$97
Omeprazole15$55
Levothyroxine Sodium11$41
Lorazepam26$17

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCLevothyroxine Sodium$46$4111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 242 radiation oncology providers in Illinois.

Other radiation oncology in O Fallon

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →